Georg-Speyer-Haus
Refine
Document Type
- Article (12) (remove)
Has Fulltext
- yes (12)
Is part of the Bibliography
- no (12)
Keywords
- HSPC (1)
- RUNX1/ETO (1)
- WYE-354 (1)
- clinical trials (1)
- epigenetics (1)
- gallbladder cancer (1)
- gallbladder cancer xenografts (1)
- iPS (1)
- leukemia (1)
- mTOR inhibitors (1)
- monogenic disorders (1)
- rapamycin (1)
- stem cell therapy (1)
- stem/progenitor cell expansion (1)
- viral vectors (1)
Institute
- Medizin (12) (remove)
Rückschläge werfen eine neue Technologie um Jahrzehnte zurück – besonders, wenn Menschenleben zu beklagen sind. Bei der Gentherapie wird aber oft vergessen, dass sie nur bei Patienten angewendet wird, für die es keine konventionelle Therapie mehr gibt. Nach der Euphorie und den Rückschlägen der Anfangsjahre können Forscher nun die ersten Erfolge vorweisen.
The leukemia-associated fusion protein RUNX1/ETO is generated by the chromosomal translocation t(8;21) which appears in about 12% of all de novo acute myeloid leukemias (AMLs). Essential for the oncogenic potential of RUNX1/ETO is the oligomerization of the chimeric fusion protein through the nervy homology region 2 (NHR2) within ETO. In previous studies, we have shown that the intracellular expression of peptides containing the NHR2 domain inhibits RUNX1/ETO oligomerization, thereby preventing cell proliferation and inducing differentiation of RUNX1/ETO transformed cells. Here, we show that introduction of a recombinant TAT-NHR2 fusion polypeptide into the RUNX1/ETO growth-dependent myeloid cell line Kasumi-1 results in decreased cell proliferation and increased numbers of apoptotic cells. This effect was highly specific and mediated by binding the TAT-NHR2 peptide to ETO sequences, as TAT-polypeptides containing the oligomerization domain of BCR did not affect cell proliferation or apoptosis in Kasumi-1 cells. Thus, the selective interference with NHR2-mediated oligomerization by peptides represents a challenging but promising strategy for the inhibition of the leukemogenic potential of RUNX1/ETO in t(8;21)-positive leukemia.